Proglumide (Milid)

05/01/2003 - "Mean pain scores fell from a baseline of 8.12-7.89 during the placebo phase (N.S.) and to 6.82 during the proglumide phase (P < 0.05). "
03/01/1986 - "Pain modulation appears to be a major effect of CCK and proglumide, its antagonist. "
06/01/1989 - "At onset of pain after the removal of impacted third molars, patients (n = 60) received intravenously either 4 mg morphine, 8 mg morphine, or 4 mg morphine plus proglumide (0.05, 0.5, or 5 mg). "
03/01/1986 - "CCK's inhibitory effect and proglumide's potentiating effect on opiate analgesia may have clinical application; proglumide's inhibitory effect on opiate tolerance may help in management of chronic pain. "
11/01/1998 - "We conclude that proglumide enhances the analgesia produced by morphine in some, but not all, patients with chronic benign pain. "

02/11/2023 - "When proglumide was given in combination with the PD-1Ab, there was a further significant increase in intratumoral CD8+ T cells, improved survival, and alterations in genes regulating tumoral fibrosis and epithelial-to-mesenchymal transition. "
03/12/2022 - "This investigation demonstrated that proglumide is safe and has similar pharmacokinetic properties in subjects with cirrhosis as in healthy controls; therefore, it will be safe to test the efficacy of proglumide as a therapeutic agent in those subjects with cirrhosis or HCC."
09/30/2021 - "Proglumide altered the expression of genes involved in fibrosis, epithelial-mesenchymal transition, and invasion. "
02/11/2023 - "RNAseq results from human HepG2 HCC cells treated with proglumide showed significant changes in differentially expressed genes involved in tumorigenesis, fibrosis, and the tumor microenvironment. "
02/11/2023 - "Results showed that proglumide decreased fibrosis in the tumor microenvironment and increased the number of intratumoral CD8+ T cells in RIL-175 tumors. "

02/11/2023 - "Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma."
03/12/2022 - "Proglumide is an orally administered cholecystokinin receptor antagonist that was found to improve nonalcoholic steatohepatitis, reverse liver fibrosis, and decrease incidence of hepatocellular carcinoma (HCC) in animal models. "

01/01/1997 - "Therefore, we have also examined the effect of proglumide on the somatostatinergic system in controls and rats with acute pancreatitis. "
03/01/1988 - "The results do not support proglumide as the sole treatment in acute pancreatitis."
03/01/1988 - "Proglumide treatment in bile-induced acute experimental pancreatitis."
01/01/1997 - "Proglumide, a CCK receptor antagonist reduces the severity of acute pancreatitis in the rat. "
01/01/1989 - "The results of this study demonstrate that CCK has an important role in the development of acute pancreatitis and that proglumide might have prophylactic and therapeutic effects in acute pancreatitis."

09/01/1987 - "Studies were conducted to clarify the possible role of CCK in cerebral ischemia and to evaluate the effects of proglumide, a competitive and reversible CCK antagonist, as a potential therapeutic or prophylactic tool in the treatment of cerebral ischemia. "
09/01/1987 - "The influence of proglumide, a putative CCK antagonist, on cerebral ischemia in gerbil."
09/01/1987 - "These results suggest that CCK may be involved in the pathological processes of cerebral ischemia and proglumide or related compounds prove to be effective in the pharmacological prophylaxis of ischemic brain damage."